« OMIG Work Plan | Main | Novello Charged, Pleads Not Guilty »

ACLU + PUBPAT lawsuit: 'Gene Patents Stifle Patient Access To Medical Care And Critical Research'

5/12/09 The Public Patent Foundation at Benjamin N. Cardozo School of Law (PUBPAT) website news (1), (2), reports that ACLU and PUBPAT filed a lawsuit charging that patents on 2 human genes associated with breast and ovarian cancer stifle research that could lead to cures and limit women's options regarding their medical care. Mutations along the genes, known as BRCA1 and BRCA2, are responsible for most cases of hereditary breast and ovarian cancers. Here are just a few excerpts from a very interesting article (1):
The lawsuit argues that the patents on these genes are unconstitutional and invalid.
The patents granted to Myriad give the company the exclusive right to perform diagnostic tests on the BRCA1 and BRCA2 genes and to prevent any researcher from even looking at the genes without first getting permission from Myriad. According to the lawsuit, such monopolistic control over these genes hampers clinical diagnosis and serves as a disincentive for research because Myriad not only has the right to enforce its patents against other entities but also has the rights to future mutations discovered on the BRCA2 gene. The gene patents are also illegal under patent law because genes are products of nature.
Many women with a history of breast and ovarian cancer in their families opt to undergo genetic testing to determine if they have the mutations on their BRCA genes that put them at increased risk for these diseases. This information is critical in helping these women decide on a plan of treatment or prevention, including increased surveillance or preventive mastectomies or ovary removal. However, the fact that Myriad can exclude others from providing this testing has several negative consequences for patients: many women cannot afford the more than $3,000 Myriad charges for the test; patients cannot get second opinions on their test results; and patients whose tests come back with inconclusive results do not have the option to seek additional testing elsewhere.
Because the ACLU/PUBPAT lawsuit challenges the whole notion of gene patenting, it could have far reaching effects beyond the patents on the BRCA genes. Approximately 20 percent of all human genes are patented, including genes associated with Alzheimer's disease, muscular dystrophy, colon cancer, asthma and many other illnesses.
(1) http://www.pubpat.org/brcafiled.htm
(2) www.aclu.org/brca

Comments (1)

I make many of the same arguments regarding innovation and science in my new book "Who Owns You?" http://www.amazon.com/Who-Owns-You-Corporate-Philosophy/dp/1405187301/ref=sr_1_1?ie=UTF8&s=books&qid=1242232286&sr=1-1

At least, I hope this brings some needed attention to this ongoing issue.

Post a comment

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)


This page contains a single entry from the blog posted on May 13, 2009 9:51 AM.

The previous post in this blog was OMIG Work Plan.

The next post in this blog is Novello Charged, Pleads Not Guilty.

Many more can be found on the main index page or by looking through the archives.